Arkolith/Insider Trading/INZY/Form 4

Bolte Axel

DirectorInozyme Pharma, Inc. (INZY) · full profile →Form 4 · filed May 20, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 15, 2025Option exercise(M)4K$0.98$4K424K
May 15, 2025Option exercise(M)153K$0.98$150K420K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 15, 2025Option exercise(M)4K—$00
May 15, 2025Option exercise(M)153K—$00

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-075148) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML